Patents by Inventor Brent Larsen Petersen

Brent Larsen Petersen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for glyco-engineering plant cells for controlled human O-glycosylation
    Patent number: 9024110
    Abstract: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon ?2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: May 5, 2015
    Inventors: Zhang Yang, Damian Paul Drew, Emma Adhiambo Arigi, Peter Ulvskov, Steven B. Levery, Eric Bennett, Henrik Clausen, Brent Larsen Petersen
  • METHODS FOR GLYCO-ENGINEERING PLANT CELLS FOR CONTROLLED HUMAN O-GLYCOSYLATION
    Publication number: 20110237782
    Abstract: This invention discloses the development of a novel platform for recombinant production of bioactive glycoproteins and cancer specific vaccines in plants. Plants and plant cell cultures have been humanized with respect to human mucin-type protein O-glycosylation. A panel of plant cell factories for production of recombinant glycoproteins with designed human O-glycosylation, including an improved cancer vaccine candidate, has been developed. The platform provides basis for i) production of an essentially unlimited array of O-glycosylated human glycoprotein therapeutics, such as human interferon ?2B and podoplanin, and ii) for further engineering of additional cancer specific O-glycans on glycoproteins of therapeutical value. Currently, mammalian cells are required for human O-glycosylation, but plants offer a unique cell platform for engineering O-glycosylation since they do not perform human type O-glycosylation.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 29, 2011
    Inventors: Zhang Yang, Damian Paul Drew, Emma Adhiambo Arigi, Peter Ulvskov, Steven B. Levery, Eric Paul Bennett, Henrik Clausen, Brent Larsen Petersen